- Trials with a EudraCT protocol (14,142)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (117)
14,142 result(s) found for: Period.
Displaying page 5 of 708.
EudraCT Number: 2009-013701-34 | Sponsor Protocol Number: VMMET009 | Start Date*: 2011-09-01 | |||||||||||
Sponsor Name:Hospital of the University of Munich | |||||||||||||
Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial | |||||||||||||
Medical condition: vestibular migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003302-24 | Sponsor Protocol Number: ESTEVE-SIGM-201 | Start Date*: 2011-11-17 |
Sponsor Name:Laboratorios Dr. Esteve S.A. (ESTEVE) | ||
Full Title: An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, as part of an analgesic ... | ||
Medical condition: post-operative pain following abdominal hysterectomy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001315-44 | Sponsor Protocol Number: TAK-935-18-002(OV935) | Start Date*: 2022-05-24 | ||||||||||||||||||||||||||
Sponsor Name:Takeda Development Center America, Inc. | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study) | ||||||||||||||||||||||||||||
Medical condition: Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002373-22 | Sponsor Protocol Number: hNSCALSII | Start Date*: 2024-05-31 |
Sponsor Name:FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS | ||
Full Title: Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical Trial | ||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001478-78 | Sponsor Protocol Number: MCT8-2021-3 | Start Date*: 2023-03-31 |
Sponsor Name:Rare Thyroid Therapeutics International AB | ||
Full Title: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double blind, Randomized, Placebo controlled Study | ||
Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004980-36 | Sponsor Protocol Number: MS200527-0082 | Start Date*: 2020-09-21 | ||||||||||||||||
Sponsor Name:Merck Healthcare KGaA | ||||||||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros... | ||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Prematurely Ended) LT (Completed) SK (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Prematurely Ended) NO (Prematurely Ended) ES (Completed) DE (Prematurely Ended) SI (Completed) IT (Prematurely Ended) RO (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005848-21 | Sponsor Protocol Number: M11-352 | Start Date*: 2013-12-18 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud... | |||||||||||||
Medical condition: Diabetic Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004586-84 | Sponsor Protocol Number: N01364 | Start Date*: 2015-11-12 | ||||||||||||||||
Sponsor Name:UCB Pharma SA | ||||||||||||||||||
Full Title: A multicenter, open-label, randomized, parallel-group, active-controlled study comparing the efficacy and safety of Levetiracetam to Carbamazepine used as monotherapy in subjects (≥16 years) newly ... | ||||||||||||||||||
Medical condition: Epilepsy Partial Seizures | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006345-14 | Sponsor Protocol Number: N01253 | Start Date*: 2015-03-09 | |||||||||||
Sponsor Name:UCB, Inc. | |||||||||||||
Full Title: An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Se... | |||||||||||||
Medical condition: Epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000460-34 | Sponsor Protocol Number: ALCAT | Start Date*: 2015-11-18 |
Sponsor Name:Hospital of the University of Munich | ||
Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) | ||
Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004543-57 | Sponsor Protocol Number: D9618C00001 | Start Date*: 2006-03-29 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg on... | ||
Medical condition: Moderate to severe asthma and symptoms of gastroesophageal reflux disease (GERD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002521-27 | Sponsor Protocol Number: 8477-CL-0020 | Start Date*: 2014-05-08 | ||||||||||||||||
Sponsor Name:Astellas Pharma Europe B.V. (APEB) | ||||||||||||||||||
Full Title: A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain | ||||||||||||||||||
Medical condition: Peripheral Neuropathic Pain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000894-56 | Sponsor Protocol Number: NAK-06 | Start Date*: 2014-02-26 | ||||||||||||||||
Sponsor Name:Menarini Ricerche S.p.A. | ||||||||||||||||||
Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg... | ||||||||||||||||||
Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004334-26 | Sponsor Protocol Number: N01222 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:UCB Japan Co. Ltd | |||||||||||||
Full Title: A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration i... | |||||||||||||
Medical condition: Epilepsies Partial | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001972-46 | Sponsor Protocol Number: SKNt-001-CP4 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: Reaching Protein Target with SmofKabiven® extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute... | |||||||||||||
Medical condition: Parenteral nutrition (PN) when oral or enteral nutrition (ON or EN) is impossible, insufficient, or contraindicated in the early phase of critical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002093-42 | Sponsor Protocol Number: SHP643-301 | Start Date*: 2020-02-04 | ||||||||||||||||
Sponsor Name:Shire (Shire is now part of Takeda) | ||||||||||||||||||
Full Title: SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (... | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005261-19 | Sponsor Protocol Number: CVAL489K2303 | Start Date*: 2007-04-23 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 6 months-5 years old with hypertension, followed by a 2 we... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) HU (Completed) FR (Completed) SE (Prematurely Ended) PL (Completed) IT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003371-13 | Sponsor Protocol Number: IM101084 | Start Date*: 2007-07-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Diseas... | |||||||||||||
Medical condition: Crohn's disease, NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IE (Completed) DK (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-004719-32 | Sponsor Protocol Number: FLT2504 | Start Date*: 2014-01-07 | |||||||||||
Sponsor Name:Mundipharma Research Ltd | |||||||||||||
Full Title: A single (assessor) - blind, randomised, three-period, cross-over study to compare the safety of flutiform® pMDI, fluticasone pMDI and beclometasone Autohaler® in paediatric subjects aged 5 to le... | |||||||||||||
Medical condition: Mild persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000940-26 | Sponsor Protocol Number: CASM981C2314 | Start Date*: 2004-09-24 |
Sponsor Name:Novartis Pharma | ||
Full Title: A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosin... | ||
Medical condition: Atopic dermatitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) AT (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
